Alirocumab

SKU: orb1219984

Description

Alirocumab is a human monoclonal antibody that inhibits PCSK9. It is produced by recombinant DNA technology in Chinese hamster ovary cell suspension culture.

Key Properties

• CAS Number: 1245916-14-6
• MW: 146 kDa
• Purity: >98% (HPLC)
• Formula: ——
• Target: PCSK9

Bioactivity

• In Vivo:
  Animal model: CETP mice model. Dosage: 3 or 10 mg/kg. Administration: s. c. Result: Decreased total cholesterol dose-dependently. Increased hepatic LDL receptor protein levels but did not affect hepatic cholesterol and TG content. Decreased atherosclerotic lesion size and improved plaque morphology. Animal model: Rat model (240-280 g). Dosage: 10 mg/kg. Administration: i.p. Result: Elevated ammonia, total cholesterol, LDL and ox-LDL levels. Decreased plasma levels of total cholesterol, LDL, and oxidative stress markers.
• In Vitro:
  Cell Viability Assay Cell line: hiPSC-CMs, hESC-CMs. Concentration: 0.01, 0.1, 1, 2, 10 μM Incubation time: 24-72 h. Result: Exhibited normal cell viability and did not affect the level of LDH release.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Quick Database Links

Gene Symbol

PCSK9